For more than two decades, women and clinicians have navigated an agonizing dilemma regarding menopausal hormone therapy (MHT), commonly called hormone replacement therapy (HRT). In 2002, the landmark Women’s Health Initiative (WHI) halted its combined hormone trial early after reporting increased risks of stroke, blood clots, and heart disease. Millions abruptly discontinued therapy, and an entire generation of women was taught to view postmenopausal hormones primarily through the lens of cardiovascular harm.
Yet a fundamental physiological question persisted: does the cardiovascular impact of hormone therapy depend on when treatment begins? A growing body of vascular research proposed the “timing hypothesis,” suggesting that estrogen preserves healthy arteries when started during perimenopause, but can harm vessels that are already atherosclerotic. Now, 20-year longitudinal data from the Study of Women’s Health Across the Nation (SWAN), published in JAMA Internal Medicine, offers definitive real-world evidence: initiating hormone therapy during perimenopause or early postmenopause is associated with a 22% lower risk of cardiovascular disease compared to non-users.
The 20-Year SWAN Findings: A Critical Look at the Evidence
The Study of Women’s Health Across the Nation (SWAN) is a multi-center, multi-ethnic prospective cohort study tracking female midlife health across the United States. In this new analysis, researchers followed more than 2,700 women over a median of 20 years. Participants entered the study without clinical heart disease and reported menopausal status, vasomotor symptoms (hot flashes and night sweats), and hormone therapy usage.
Led by senior author Dr. Samar R. El Khoudary at Virginia Commonwealth University, the investigators observed three key findings:
- 22% Lower Overall Cardiovascular Risk: Women initiating hormone therapy during perimenopause or early postmenopause experienced a 22% lower rate of cardiovascular events over 20 years.
- The 10-Year Opportunity Window: Protection was most pronounced among women who started within 10 years of menopause onset, demonstrating a 27% risk reduction.
- Marked Reduction in Black Women: In ethnic subgroup analyses, Black women initiating therapy early experienced an estimated 49% reduction in cardiovascular disease events.
Because SWAN is an observational cohort rather than a randomized trial, these results demonstrate a strong longitudinal association rather than definitive causation. Potential confounding from socioeconomic factors or the “healthy-user effect” cannot be entirely ruled out. Nevertheless, two decades of follow-up across a diverse cohort provide real-world confirmation of the vascular timing hypothesis.
The Vascular Biology: Why Arterial Health Dictates Outcomes
According to the World Health Organization, cardiovascular disease is the leading cause of death in women globally, claiming roughly one in three lives. Endogenous estrogen naturally protects the female vascular system before menopause. During the menopause transition, plunging estradiol levels accelerate arterial stiffening, unfavorable lipid shifts, and endothelial dysfunction.
The cardiovascular response to supplemental estrogen depends directly on baseline arterial health:
- Healthy Endothelium (Perimenopause / Early Menopause): In elastic, non-diseased arteries, estradiol activates endothelial nitric oxide synthase (eNOS). This promotes vasodilation, reduces oxidative stress, limits smooth muscle proliferation, and maintains vascular compliance.
- Atherosclerotic Vessels (Late Postmenopause): When estrogen is introduced 10 to 15 years after menopause into arteries with advanced calcified plaques—as occurred in the original WHI cohort whose average age was 63—estrogen can upregulate matrix metalloproteinases. This enzymatic activity may destabilize fibrous plaque caps, promoting thrombosis and ischemic events.
This biological divergence, detailed in reviews by the National Heart, Lung, and Blood Institute and in PubMed Central, explains why early initiation supports vascular health while late initiation may introduce risk.
Vasomotor Symptoms: A Direct Biomarker of Heart Health
A crucial insight from the SWAN analysis is that hot flashes and night sweats are not merely benign quality-of-life complaints. Cardiovascular epidemiologists increasingly recognize frequent or severe vasomotor symptoms as clinical indicators of autonomic dysregulation and endothelial dysfunction.
Women with persistent vasomotor symptoms exhibit higher sympathetic tone, greater arterial stiffness, higher ambulatory blood pressure, and adverse lipid profiles (elevated apolipoprotein B and small dense LDL particles). In SWAN, symptomatic women receiving early hormone therapy achieved the most significant cardiovascular risk reductions. Treating vasomotor reactivity during the transition appears to deliver dual benefits: symptomatic relief and vascular support.
Comparing Hormone Therapy Timing Across Major Trials
The table below summarizes participant demographics, timing protocols, and cardiovascular findings across landmark hormone therapy trials over three decades.
| Study & Design | Participant Age & Timing | Regimen | Primary Cardiovascular Finding |
|---|---|---|---|
| WHI Trial (2002) RCT (n=16,608) |
Average age 63.3; >10 years postmenopause | Oral CEE + medroxyprogesterone | Elevated coronary events and stroke in older women; trial stopped early. |
| ELITE Trial (2016) Mechanistic RCT (n=643) |
Stratified: <6 yrs vs. ≥10 yrs postmenopause | Oral 17β-estradiol + vaginal progesterone | Slower carotid plaque progression in women starting <6 years; no benefit in late starters. |
| SWAN Cohort (2026) Prospective cohort (n=2,700+) |
Initiation in perimenopause or <10 yrs postmenopause | Clinical practice MHT in symptomatic women | 22% lower cardiovascular risk overall; 27% lower if started <10 years; 49% lower in Black women. |
Source: Synthesized from comparative cohort and trial data published in JAMA Internal Medicine (SWAN, 2026), New England Journal of Medicine (ELITE, 2016), and JAMA (WHI, 2002).
Clinical Guidelines: Evaluating Candidacy and Safety
Major medical organizations—including The Menopause Society, the American College of Obstetricians and Gynecologists, and the American Heart Association—provide clear guidance on candidate evaluation:
- Approved Indications: Hormone therapy remains the most effective approved treatment for moderate-to-severe vasomotor symptoms and prevention of bone loss. Current guidelines do not recommend initiating MHT solely for primary cardiovascular disease prevention in asymptomatic women.
- The Opportunity Window: For healthy women under age 60 or within 10 years of menopause onset who suffer from bothersome symptoms, the risk-benefit balance is favorable.
- Route of Administration: Modern care often utilizes transdermal estradiol patches or gels, which bypass hepatic first-pass metabolism and do not stimulate hepatic clotting factors, conferring a lower baseline risk of venous thromboembolism than oral estrogens. Women with an intact uterus require concurrent progesterone to protect against endometrial hyperplasia.
- Contraindications: Unexplained vaginal bleeding, active liver disease, history of estrogen-sensitive cancers, prior stroke, or venous thromboembolism remain contraindications. Baseline cardiovascular risk calculation should always precede prescription.
Navigating Your Midlife Cardiovascular Strategy
Perimenopause is a critical cardiovascular inflection point. Rather than enduring symptoms passively, women should use this phase as a catalyst for comprehensive cardiovascular risk profiling. In addition to discussing hormone therapy eligibility with a clinician, evidence-based lifestyle habits are vital:
- Comprehensive Biomarker Screening: Tracking blood pressure, lipid panels (including ApoB), and fasting blood glucose.
- Targeted Physical Activity: Combining resistance exercise to maintain lean mass with zone 2 aerobic training to support vascular compliance.
- Cardioprotective Nutrition: Adopting a Mediterranean dietary pattern rich in leafy vegetables, olive oil, and fiber.
- Sleep and Stress Care: Protecting circadian rhythm and mitigating chronic autonomic stress.
The 20-year findings from SWAN show that when considering hormone therapy, timing is not a minor detail—it is the foundational variable.
Related Reading
- Perimenopause and Heart Health: A Critical Window for Women
- Menopause, HRT Timing, and Dementia Risk: New Research
- Menopause Hormone Therapy: New Research on Bone Loss
Sources and Further Reading
- El Khoudary SR, et al. Timing of Menopausal Hormone Therapy and Cardiovascular Outcomes in the Study of Women’s Health Across the Nation (SWAN). JAMA Internal Medicine. September 2026.
- Study of Women’s Health Across the Nation (SWAN). Longitudinal Multi-Ethnic Research on the Menopause Transition. SWAN Study Research Portal.
- Manson JE, et al. Menopausal Hormone Therapy and Extended Health Outcomes: Lessons From the Women’s Health Initiative. PubMed Central (PMC) Clinical Review.
- National Heart, Lung, and Blood Institute (NHLBI). Coronary Heart Disease in Women: Pathophysiology and Prevention. NIH NHLBI Health Topics.
- World Health Organization. Cardiovascular Diseases (CVDs) Global Burden and Prevention. WHO Official Health Topics.
- American Heart Association (AHA). Menopause Transition and Cardiovascular Disease Risk: Statement on Timing and Prevention. AHA Clinical Guidance.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.